questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Effets physiologiques des médicaments
Facteurs immunologiques
Immunosuppresseurs
Immunosuppresseurs : Questions médicales fréquentes
Diagnostic
5
Maladies auto-immunes
Tests sanguins
Rejet d'organe
Tests de compatibilité
Fatigue
Douleurs articulaires
Symptômes
5
Effets secondaires
Infections
Allergies
Éruptions cutanées
Réaction indésirable
Saignements
Prévention
5
Prévention des infections
Vaccination
Sécurité alimentaire
Infections alimentaires
Gestion du stress
Soutien psychologique
Suivi médical
Fonction rénale
Interactions médicamenteuses
Consultation médicale
Traitements
5
Corticostéroïdes
Inhibiteurs de calcineurine
Voie orale
Administration intraveineuse
Durée du traitement
Maladies chroniques
Thérapies biologiques
Médicaments anti-inflammatoires
Complications
5
Complications
Infections graves
Risque de cancer
Immunosuppression
Gestion des complications
Suivi médical
Facteurs de risque
5
Antécédents médicaux
Maladies auto-immunes
Mode de vie
Réponse au traitement
Antibiotiques
Interactions médicamenteuses
Antécédents familiaux
Maladies auto-immunes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Immunosuppresseurs : Questions médicales les plus fréquentes",
"headline": "Immunosuppresseurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Immunosuppresseurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs immunologiques",
"url": "https://questionsmedicales.fr/mesh/D007155",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs immunologiques",
"code": {
"@type": "MedicalCode",
"code": "D007155",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du complément",
"alternateName": "Complement Inactivating Agents",
"url": "https://questionsmedicales.fr/mesh/D051056",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du complément",
"code": {
"@type": "MedicalCode",
"code": "D051056",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"alternateName": "Bradykinin B2 Receptor Antagonists",
"url": "https://questionsmedicales.fr/mesh/D065094",
"about": {
"@type": "MedicalCondition",
"name": "Antagonistes du récepteur B2 de la bradykinine",
"code": {
"@type": "MedicalCode",
"code": "D065094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des interleukines",
"alternateName": "Interleukin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000088902",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des interleukines",
"code": {
"@type": "MedicalCode",
"code": "D000088902",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.563"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'interleukine-6",
"alternateName": "Interleukin-6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000093242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'interleukine-6",
"code": {
"@type": "MedicalCode",
"code": "D000093242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.594"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"alternateName": "Sphingosine 1 Phosphate Receptor Modulators",
"url": "https://questionsmedicales.fr/mesh/D000081243",
"about": {
"@type": "MedicalCondition",
"name": "Modulateurs des récepteurs de la sphingosine 1 phosphate",
"code": {
"@type": "MedicalCode",
"code": "D000081243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.477.656.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Immunosuppresseurs",
"alternateName": "Immunosuppressive Agents",
"code": {
"@type": "MedicalCode",
"code": "D007166",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Koichi Kamei",
"url": "https://questionsmedicales.fr/author/Koichi%20Kamei",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp."
}
},
{
"@type": "Person",
"name": "Masao Ogura",
"url": "https://questionsmedicales.fr/author/Masao%20Ogura",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Kensuke Shoji",
"url": "https://questionsmedicales.fr/author/Kensuke%20Shoji",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Shuichi Ito",
"url": "https://questionsmedicales.fr/author/Shuichi%20Ito",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan."
}
},
{
"@type": "Person",
"name": "Dorota Iwaszkiewicz-Grześ",
"url": "https://questionsmedicales.fr/author/Dorota%20Iwaszkiewicz-Grze%C5%9B",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "New immunosuppressive agents in transplantation.",
"datePublished": "2022-10-15",
"url": "https://questionsmedicales.fr/article/36252821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lpm.2022.104142"
}
},
{
"@type": "ScholarlyArticle",
"name": "Live attenuated vaccines in patients receiving immunosuppressive agents.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37076756",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00467-023-05969-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treat-to-Target: The Era of Targeted Immunosuppressive Agents in IBD Management.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36300960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis.",
"datePublished": "2022-12-23",
"url": "https://questionsmedicales.fr/article/36566826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijpharm.2022.122535"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37567010",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.intimp.2023.110577"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Facteurs immunologiques",
"item": "https://questionsmedicales.fr/mesh/D007155"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunosuppresseurs",
"item": "https://questionsmedicales.fr/mesh/D007166"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Immunosuppresseurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Immunosuppresseurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-28",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Immunosuppresseurs",
"description": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?\nQuels tests sont utilisés pour évaluer l'immunité ?\nQuels signes indiquent un besoin d'immunosuppresseurs ?\nComment évaluer le risque de rejet d'organe ?\nQuels symptômes nécessitent un traitement immunosuppresseur ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Immunosuppresseurs",
"description": "Quels sont les effets secondaires des immunosuppresseurs ?\nComment reconnaître une infection due à l'immunosuppression ?\nQuels symptômes d'allergie peuvent survenir ?\nLes immunosuppresseurs causent-ils des troubles digestifs ?\nQuels signes indiquent une réaction indésirable ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Immunosuppresseurs",
"description": "Comment prévenir les infections sous immunosuppression ?\nQuelles précautions alimentaires prendre ?\nComment gérer le stress pendant le traitement ?\nQuels examens de suivi sont nécessaires ?\nComment éviter les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Immunosuppresseurs",
"description": "Quels types d'immunosuppresseurs existent ?\nComment sont administrés les immunosuppresseurs ?\nQuelle est la durée du traitement immunosuppresseur ?\nComment ajuster la posologie des immunosuppresseurs ?\nQuels sont les traitements alternatifs aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Immunosuppresseurs",
"description": "Quelles sont les complications possibles des immunosuppresseurs ?\nComment reconnaître une infection grave ?\nLes immunosuppresseurs augmentent-ils le risque de cancer ?\nQuels troubles métaboliques peuvent survenir ?\nComment gérer les complications liées aux immunosuppresseurs ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Immunosuppresseurs",
"description": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?\nComment l'âge influence-t-il le traitement ?\nLe mode de vie affecte-t-il l'immunosuppression ?\nQuels médicaments augmentent le risque d'interactions ?\nLes antécédents familiaux influencent-ils le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D007166#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique et des tests sanguins pour évaluer l'auto-immunité."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'immunité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme le dosage des anticorps et des lymphocytes T sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin d'immunosuppresseurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des inflammations chroniques ou des éruptions cutanées peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque de rejet d'organe ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests de compatibilité et des marqueurs immunologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un traitement immunosuppresseur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue extrême ou des douleurs articulaires peuvent nécessiter un traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des immunosuppresseurs ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent infections, fatigue, et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection due à l'immunosuppression ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme fièvre, frissons ou douleurs inhabituelles peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'allergie peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent être des signes d'allergie."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs causent-ils des troubles digestifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction indésirable ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs abdominales ou des saignements peuvent signaler une réaction."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections sous immunosuppression ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de se faire vacciner et d'éviter les contacts avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quelles précautions alimentaires prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les aliments crus et assurez-vous que les aliments sont bien cuits pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Quels examens de suivi sont nécessaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction rénale et des tests sanguins sont nécessaires pour le suivi."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informez toujours votre médecin de tous les médicaments que vous prenez pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quels types d'immunosuppresseurs existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux types incluent les corticostéroïdes, les inhibiteurs de calcineurine et les agents biologiques."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les immunosuppresseurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou sous-cutanée selon le médicament."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement immunosuppresseur ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon la maladie, allant de quelques mois à plusieurs années."
}
},
{
"@type": "Question",
"name": "Comment ajuster la posologie des immunosuppresseurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie est ajustée en fonction des résultats des tests sanguins et de la réponse clinique."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements alternatifs aux immunosuppresseurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements alternatifs incluent des thérapies biologiques et des médicaments anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des immunosuppresseurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections graves, des cancers et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection grave ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme une forte fièvre, des frissons ou une confusion peuvent indiquer une infection grave."
}
},
{
"@type": "Question",
"name": "Les immunosuppresseurs augmentent-ils le risque de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée d'immunosuppresseurs peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Quels troubles métaboliques peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles comme le diabète ou l'hypertension peuvent survenir avec certains immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux immunosuppresseurs ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi régulier, des ajustements de traitement et une surveillance des symptômes."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies auto-immunes ou de transplantation augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru d'effets secondaires et nécessiter des ajustements."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'immunosuppression ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques d'infections et améliorer la réponse au traitement."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque d'interactions ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains antibiotiques et antifongiques peuvent interagir avec les immunosuppresseurs."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies auto-immunes peuvent augmenter le risque de développer des maladies similaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp.
Publications dans "Immunosuppresseurs" :
4 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
4 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Organic Chemistry, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, 80-233 Gdańsk, Poland.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil. Electronic address: luana.farma@hotmail.com.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Department of Preventive Veterinary Medicine, Veterinary School, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmacology, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Postgraduate Program in Pharmaceutical Sciences, Health Sciences Centre, Federal University of Santa Maria (UFSM), Santa Maria, RS, Brazil.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, University of California, San Diego, CA.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
2 publications dans cette catégorie
Affiliations :
Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Publications dans "Immunosuppresseurs" :
Immunosuppressive agents have enabled the development of allogenic transplantation during the last 40 years, allowing considerable improvement in graft survival. However, several issues remain such as...
The use of live attenuated vaccines in patients with immunosuppressive agents is contraindicated in package inserts and guidelines in Japan and other countries. However, patients receiving immunosuppr...
With the advent of biologic agents, the treatment of patients with Inflammatory Bowel Diseases (IBD) has changed from managing symptoms to achieving remission of disease. Disease remission is associat...
Psoriasis is a recurring, immune-mediated dermatological disorder. Many therapeutic agents are available for the treatment of psoriasis, including immunosuppressants and biologic treatments with immun...
Immunosuppression is an integral part of treating chronic spontaneous urticaria (CSU), but there is no literature to evaluate the efficacy of multiple immunosuppressive agents....
The comparison of the efficacy, safety, and incidence of adverse effects of four immunosuppressive medicines (tripterygium glycosides, methotrexate, cyclosporine A, and azathioprine) in combination wi...
PUBMED, The Cochrane Library, EMBASE, WANFANG, CNKI, CBM, and clinical trial registration platform were searched to collect relevant randomized controlled trials (RCT) and cohort studies of four immun...
This study pooled data from seven randomized clinical trials with 410 participants. The standardized mean differences for change in UAS7 were 0.10 (95% confidence interval (CI), 0.01 to 0.68) for cycl...
Our results indicate that cyclosporine A combined with antihistamine resulted in greater improvements regarding the UAS7 in CSU patients and that tripterygium glycosides are also effective in treating...
Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was...
A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated wit...
61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) w...
Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment....
Human polyomavirus BK (BKPyV) is the etiologic agent of polyomavirus-associated nephropathy, a leading cause of kidney transplant dysfunction. Because of the lack of antiviral therapies, immunosuppres...
Human renal tubular epithelial cells were infected with BKPyV and treated with leflunomide, tacrolimus, mycophenolic acid, sirolimus, and everolimus, administered alone or in some combination thereof....
The highest inhibitory effects were observed using leflunomide or everolimus plus mycophenolic acid (mean BKPyV replication log reduction 0.28). The antiviral effect of everolimus persisted when it wa...
Our experience confirms that everolimus has anti-BKPyV properties and prompts future research to investigate possible mechanisms of action. It also provides a rational basis for targeted clinical tria...
Although live-attenuated vaccines are contraindicated under immunosuppression, the immune status of patients with inflammatory bowel disease (IBD) has not been fully assessed prior to immunosuppressiv...
To investigate antiviral serostatus against viruses requiring live vaccines for prevention in IBD patients undergoing immunosuppressive therapy....
This multicenter study included IBD patients who were aged <40 years and were treated with thiopurine monotherapy, molecular-targeted monotherapy, or combination therapy. Gender- and age-matched healt...
A total of 437 IBD patients (163 ulcerative colitis [UC] and 274 Crohn's disease [CD]) and 225 HS were included in the final analysis. Compared with HS, IBD patients had lower seropositivity rates for...
IBD patients, especially those with UC, exhibit reduced seropositivity rates and may benefit from screening prior to the initiation of immunosuppressive therapy....
The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE) versus those without SLE. Some immunosuppressive medications increase COVID-19 infection and decrease th...
We collected information on COVID-19 infection, vaccination history, and COVID-19 antibodies in the Hopkins Lupus Cohort. A cohort of health care workers was used for comparison. Outcome measures incl...
The analysis was based on 365 observations from 334 different patients in the SLE cohort, and 2,235 observations from 1,887 different health care workers. SLE patients taking immunosuppressive medicat...
SLE patients, regardless of background immunosuppressive therapy, had lower vaccine IgG levels than health care workers. Mycophenolate, tacrolimus, and belimumab significantly reduced IgG response to ...
Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by d...
Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology....
In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immuno...
Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines i...